Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Summary

This phase II trial studies how well danvatirsen and durvalumab work in treating patients with pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer that has spread to other places in the body and does not respond to treatment. Danvatirsen may be used to block the production of proteins needed for tumor cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving danvatirsen and durvalumab may work better at treating pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer.

Conditions

• Advanced Colorectal Carcinoma
• Advanced Lung Non-Small Cell Carcinoma
• Lung Non-Small Cell Carcinoma
• Mismatch Repair Deficiency
• Refractory Colorectal Carcinoma
• Refractory Lung Carcinoma
• Refractory Pancreatic Carcinoma
• Stage II Pancreatic Cancer AJCC v8
• Stage III Colorectal Cancer AJCC v8
• Stage III Lung Cancer AJCC v8
• Stage III Pancreatic Cancer AJCC v8
• Stage IIIA Colorectal Cancer AJCC v8
• Stage IIIA Lung Cancer AJCC v8
• Stage IIIB Colorectal Cancer AJCC v8
• Stage IIIB Lung Cancer AJCC v8
• Stage IIIC Colorectal Cancer AJCC v8
• Stage IIIC Lung Cancer AJCC v8
• Stage IV Colorectal Cancer AJCC v8
• Stage IV Lung Cancer AJCC v8
• Stage IV Pancreatic Cancer AJCC v8
• Stage IVA Colorectal Cancer AJCC v8
• Stage IVA Lung Cancer AJCC v8
• Stage IVB Colorectal Cancer AJCC v8
• Stage IVB Lung Cancer AJCC v8
• Stage IVC Colorectal Cancer AJCC v8

Interventions

DRUG

Danvatirsen

Given IV

BIOLOGICAL

Durvalumab

Given IV

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• AstraZeneca

  collaborator INDUSTRY

• M.D. Anderson Cancer Center

  lead OTHER

Principal Investigators

• David S Hong · M.D. Anderson Cancer Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-03-02

Primary Completion

2025-08-30

Completion

2025-08-30

FDA Drug

Yes

Countries

• United States

Study Locations